- Home
- ACIU vs YMAB Comparison
ACIU vs YMAB Comparison
Compare ACIU & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- YMAB
- Stock Information
- Founded
- ACIU 2003
- YMAB 2015
- Country
- ACIU Switzerland
- YMAB United States
- Employees
- ACIU N/A
- YMAB N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ACIU Health Care
- YMAB Health Care
- Exchange
- ACIU Nasdaq
- YMAB Nasdaq
- Market Cap
- ACIU 247.4M
- YMAB 218.4M
- IPO Year
- ACIU 2016
- YMAB 2018
- Fundamental
- Price
- ACIU $1.48
- YMAB $4.69
- Analyst Decision
- ACIU Strong Buy
- YMAB Buy
- Analyst Count
- ACIU 2
- YMAB 11
- Target Price
- ACIU $12.00
- YMAB $18.73
- AVG Volume (30 Days)
- ACIU 192.5K
- YMAB 316.2K
- Earning Date
- ACIU 05-12-2025
- YMAB 05-06-2025
- Dividend Yield
- ACIU N/A
- YMAB N/A
- EPS Growth
- ACIU N/A
- YMAB N/A
- EPS
- ACIU N/A
- YMAB N/A
- Revenue
- ACIU $30,136,397.00
- YMAB $87,685,000.00
- Revenue This Year
- ACIU N/A
- YMAB N/A
- Revenue Next Year
- ACIU $676.94
- YMAB $21.10
- P/E Ratio
- ACIU N/A
- YMAB N/A
- Revenue Growth
- ACIU 84.51
- YMAB 3.38
- 52 Week Low
- ACIU $1.43
- YMAB $3.86
- 52 Week High
- ACIU $4.98
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- ACIU 24.24
- YMAB 47.75
- Support Level
- ACIU $1.48
- YMAB $4.46
- Resistance Level
- ACIU $1.62
- YMAB $5.44
- Average True Range (ATR)
- ACIU 0.12
- YMAB 0.45
- MACD
- ACIU -0.00
- YMAB 0.07
- Stochastic Oscillator
- ACIU 9.43
- YMAB 52.53
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.